MiMedx Group Inc
Change company Symbol lookup
Select an option...
MDXG MiMedx Group Inc
PM Philip Morris International Inc
BHR Braemar Hotels & Resorts Inc
ESALY Eisai Co Ltd
CNX CNX Resources Corp
WW WW International Inc
IBM International Business Machines Corp
NEP Nextera Energy Partners LP
TMP Tompkins Financial Corp
MFM MFS Municipal Income Trust
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Closing Price
$5.86
Day's Change
-0.52 (-8.15%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.37
Day's Low
5.52
Volume
(Heavy Day)
Volume:
242,793

10-day average volume:
151,562
242,793

MDXG's position in the Biotechnology industry

Industry PeersMDXGVCELRCELORGOATHX

Summary

Company ProfileMiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative...
Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and...
Go to VCEL summary
AVITA Therapeutics, Inc. is a regenerative medicine company with a technology platform to address medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics...
Go to RCEL summary
Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company. The Company focuses on the development, manufacture and commercialization of...
Go to ORGO summary
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its...
Go to ATHX summary
52-Week Change

VS. INDUSTRY
14.90%
33.18%
-49.64%
-42.56%
21.97%
Market Cap

VS. INDUSTRY
$650.7M
$938.9M
$508.0M
$443.8M
$317.8M
Beta

VS. INDUSTRY
1.5
3.1
1.1
0.9
-1.8
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
7,830.19x
--
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$280.6M
$116.6M
--
$269.6M
$10.0K
Profit Margin

VS. INDUSTRY
-2.99%
0.00%
--
-13.58%
-559,540.00%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
-10.49%
14.54%
--
-14.55%
-99.90%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.